AlloVir, Inc. – NASDAQ:ALVR
AlloVir stock price today
$11.802
+11.34
+2482.49%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in about 16 hours
AlloVir stock price monthly change
-42.87%
month
AlloVir stock price quarterly change
-42.87%
quarter
AlloVir stock price yearly change
-34.63%
year
AlloVir key metrics
Market Cap | 50.84M |
Enterprise value | 212.91M |
P/E | -1.73 |
EV/Sales | N/A |
EV/EBITDA | -1.26 |
Price/Sales | N/A |
Price/Book | 1.26 |
PEG ratio | -0.08 |
EPS | -1.65 |
Revenue | N/A |
EBITDA | -160.71M |
Income | -179.53M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAlloVir stock price history
AlloVir stock forecast
AlloVir financial statements
| Jun 2023 | 0 | -45.26M | |
|---|---|---|---|
| Sep 2023 | 0 | -44.27M | |
| Dec 2023 | 8.38M | -59.69M | -712.36% |
| Mar 2024 | 0 | -30.29M |
| Sep 2023 | 0 | -44.27M | |
|---|---|---|---|
| Dec 2023 | 8.38M | -59.69M | -712.36% |
| Mar 2024 | 0 | -30.29M | |
| Dec 2025 | 0 | -20.64M |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 282692000 | 53.57M | 18.95% |
|---|---|---|---|
| Sep 2023 | 248312000 | 52.97M | 21.34% |
| Dec 2023 | 190796000 | 45.01M | 23.59% |
| Mar 2024 | 144143000 | 23.70M | 16.44% |
| Jun 2023 | -27.12M | 37.89M | 70.48M |
|---|---|---|---|
| Sep 2023 | -34.47M | -66.85M | 0 |
| Dec 2023 | -30.73M | 25.21M | 11K |
| Mar 2024 | -44.38M | 40M | 0 |
AlloVir alternative data
| Aug 2023 | 111 |
|---|---|
| Sep 2023 | 113 |
| Oct 2023 | 113 |
| Nov 2023 | 113 |
| Dec 2023 | 114 |
| Jan 2024 | 114 |
| Feb 2024 | 114 |
| Mar 2024 | 112 |
| Apr 2024 | 112 |
| May 2024 | 112 |
| Jun 2024 | 15 |
| Jul 2024 | 15 |
AlloVir other data
39.18%
-5.13%
of ALVR is owned by hedge funds
53
-33
30.03M
-7.60M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Dec 2023 | 0 | 28335 |
| Jan 2024 | 0 | 18267 |
| Feb 2024 | 0 | 97587 |
| Apr 2024 | 0 | 18382 |
| May 2024 | 0 | 31433 |
| Jul 2024 | 0 | 18593 |
| Aug 2024 | 0 | 32719 |
| Oct 2024 | 0 | 18657 |
| Nov 2024 | 0 | 32550 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Sale | HAGEN BRETT R officer: Chief Accounting Officer | Common Stock | 554 | $0.55 | $304 | ||
Sale | SINHA VIKAS director, 10 percent owner, off.. | Common Stock | 3,186 | $0.55 | $1,749 | ||
Sale | MILLER EDWARD officer: General Counsel | Common Stock | 432 | $0.55 | $237 | ||
Sale | BRAINARD DIANA director, officer.. | Common Stock | 8,706 | $0.55 | $4,780 | ||
Sale | BRAINARD DIANA director, officer.. | Common Stock | 10,609 | $0.87 | $9,177 | ||
Sale | MILLER EDWARD officer: General Counsel | Common Stock | 2,272 | $0.87 | $1,965 | ||
Sale | HAGEN BRETT R officer: Chief Accounting Officer | Common Stock | 1,655 | $0.87 | $1,432 | ||
Sale | SINHA VIKAS director, 10 percent owner, off.. | Common Stock | 5,136 | $0.87 | $4,443 | ||
Sale | SINHA VIKAS director, 10 percent owner, off.. | Common Stock | 1,882 | $0.77 | $1,445 | ||
Sale | HAGEN BRETT R officer: Chief Accounting Officer | Common Stock | 486 | $0.77 | $373 |
| Quarter | Transcript |
|---|---|
| Q4 2012 4 Mar 2013 | Q4 2012 Earnings Call Transcript |
| Q3 2012 14 Nov 2012 | Q3 2012 Earnings Call Transcript |
| Q2 2012 2 Aug 2012 | Q2 2012 Earnings Call Transcript |
| Q1 2010 4 May 2010 | Q1 2010 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. David L. Hallal (1966) Executive Chairman | $981,020 |
Mr. Vikas Sinha C.A., CPA, M.B.A. (1963) Pres, Chief Financial Officer & Director | $654,900 |
| Dr. Ercem Atillasoy M.D. (1964) Chief Regulatory & Safety Officer | $572,460 |
| Dr. Diana M. Brainard M.D. (1971) Chief Executive Officer & Director | $20,000 |
AlloVir: Several Late-Stage Programs Make This Worth A Look
AlloVir: Solid Data, But Market Isn't Paying Attention
AlloVir: A Comparative Study Of Its Manufacturing Process
AlloVir, Inc.: Creating Solutions For Stem Cell Transplant Issues
AlloVir: Targeting Infectious Diseases In Stem Cell Transplant Patients
-
What's the price of AlloVir stock today?
One share of AlloVir stock can currently be purchased for approximately $11.8.
-
When is AlloVir's next earnings date?
Unfortunately, AlloVir's (ALVR) next earnings date is currently unknown.
-
Does AlloVir pay dividends?
No, AlloVir does not pay dividends.
-
How much money does AlloVir make?
AlloVir has a market capitalization of 50.84M.
-
What is AlloVir's stock symbol?
AlloVir, Inc. is traded on the NASDAQ under the ticker symbol "ALVR".
-
What is AlloVir's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AlloVir?
Shares of AlloVir can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AlloVir's key executives?
AlloVir's management team includes the following people:
- Mr. David L. Hallal Executive Chairman(age: 59, pay: $981,020)
- Mr. Vikas Sinha C.A., CPA, M.B.A. Pres, Chief Financial Officer & Director(age: 62, pay: $654,900)
- Dr. Ercem Atillasoy M.D. Chief Regulatory & Safety Officer(age: 61, pay: $572,460)
- Dr. Diana M. Brainard M.D. Chief Executive Officer & Director(age: 54, pay: $20,000)
-
How many employees does AlloVir have?
As Jul 2024, AlloVir employs 15 workers, which is 87% less then previous quarter.
-
When AlloVir went public?
AlloVir, Inc. is publicly traded company for more then 5 years since IPO on 30 Jul 2020.
-
What is AlloVir's official website?
The official website for AlloVir is allovir.com.
-
Where are AlloVir's headquarters?
AlloVir is headquartered at 1100 Winter Street, Waltham, MA.
-
How can i contact AlloVir?
AlloVir's mailing address is 1100 Winter Street, Waltham, MA and company can be reached via phone at +61 74332605.
AlloVir company profile:
AlloVir, Inc.
allovir.comExchange:
NASDAQ
Full time employees:
8
Industry:
Biotechnology
Sector:
Healthcare
Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108. The company was formerly known as ViraCyte, Inc. and changed its name to Allovir, Inc. in May 2019. Allovir, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
1100 Winter Street
Waltham, MA 02451
Waltham, MA 02451
CIK: 0001754068
ISIN: US0198181036
CUSIP: 019818103
